Qube Research & Technologies LTD Protalix Bio Therapeutics, Inc. Transaction History

Qube Research & Technologies LTD

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$1.88 - $2.69 $176,609 - $252,701	93,941 Added 377.77%	118,808 $304,000
Q4 2024 Feb 14, 2025	SELL	$0.99 - $1.92 $11,455 - $22,216	-11,571 Reduced 31.76%	24,867 $47,000
Q3 2024 Nov 14, 2024	SELL	$0.9 - $1.17 $76,132 - $98,972	-84,592 Reduced 69.89%	36,438 $37,000
Q2 2024 Aug 14, 2024	BUY	$1.1 - $1.32 $133,133 - $159,759	121,030 New	121,030 $141,000

8.72M

168K

31.4K

Ticker PLX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,753,400
Market Cap $96.5M
Description
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.